Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: LOBEF )

0.0120 UNCHANGED
Streaming Delayed Price Updated: 3:41 PM EST, Nov 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about LOBEF

< Previous 1 2 Next >
Lobe Sciences, Ltd. Announces the Appointment of Enclave Capital and Peak Asset Management to Fund Clinical Trials of Conjugated Psilocin™
From Lobe Sciences, Ltd.
Via Business Wire
Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™
From Lobe Sciences, Ltd.
Via Business Wire
Lobe Sciences Announces Creation of Wholly Owned Subsidiary, Alera Pharma, Inc.
From Lobe Sciences Ltd
Via Business Wire
Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!
By Richard Dal Monte 
Via TheNewswire.com
Mass-Scale Psilocin Clinical Supplies Are Ready For Upcoming Trials
Canadian biotech company Lobe Sciences Ltd. 
Via Benzinga
Lobe Sciences Announces Appointment of a New Board of Directors and Executive Management Team
From Lobe Sciences Ltd
Via Business Wire
Lobe Sciences Announces Update
From Lobe Sciences Ltd.
Via Business Wire
Wesley Ramjeet to Join Lobe Sciences’ Board of Directors, Bringing Decades of Strategic Financial Expertise
From Lobe Sciences Ltd.
Via Business Wire
Lobe Sciences Announces Frederick D. Sancilio Ph.D. to Join Board of Directors
From Lobe Sciences Ltd.
Via Business Wire
Former Merck Director and Vanderbilt Vice-Chancellor, Dr. Harry Jacobson, to Join Lobe Sciences Board of Directors
From Lobe Sciences Ltd.
Via Business Wire
Lobe Sciences Ltd. and Clearway Global Announce Change of Control and Focus on Creating Value for Shareholders
From Lobe Sciences Ltd.
Via Business Wire
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.  
Via Benzinga
Lobe Sciences Provides Company Review of 2023
From Lobe Sciences Ltd.
Via Business Wire
Lobe Sciences Provides Update on L-130 Clinical Program
From Lobe Sciences Ltd.
Via Business Wire
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound
From Lobe Sciences Ltd.
Via Business Wire
Lobe Sciences, Ltd. Announces Amendment to the Acquisition of Altemia™ & Company
From Lobe Sciences Ltd.
Via Business Wire
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
World's Largest Psychedelics Conference Boasts 12K Attendees 
Via Benzinga
This Biotech Is Entering The Clinical Stage With A Psilocin Analog Targeting Cluster Headaches
Lobe Sciences Ltd. (OTCQB: LOBEF), a biopharmaceutical company focused on non-hallucinatory doses of stabilized psychedelic-based compounds to treat rare diseases, has commenced its Phase 1 clinical... 
Via Benzinga
Lobe Sciences Initiates Phase 1 Clinical Trial of L-130
From Lobe Sciences Ltd.
Via Business Wire
Lobe Sciences Appoints Baxter Phillips III, MBA as Chief Operating Officer
From Lobe Sciences Ltd.
Via Business Wire
Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia™
From Lobe Sciences Ltd.
Via Business Wire
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... 
Via Benzinga
Psyched Business: Lobe Buys Rare Disease Treatment, Plus Healing CREI And Heally Team Up
Orphan and rare diseases drug company Lobe Sciences Ltd. (OTCQB: LOBEF) is set to acquire Altemia & Company LLC. 
Via Benzinga
Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!
As early as the 1950s, scientists were researching the possible therapeutic benefits of psychedelics such as LSD and psilocybin mushrooms. 
Via Benzinga
Chronic Cluster Headaches, Next Target For This Non-Hallucinogenic Psychedelic
Lobe Sciences (OTCQB: LOBEF), the psychedelics company performing drug R&D with sub-hallucinatory doses of psychedelics has signed a research agreement with headache medicine specialist Dr. Lauren R. 
Via Benzinga
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Economy
Exposures Supply Chain
Lobe Sciences, Ltd. Enters Collaborative Clinical Research Agreement with Integrative Headache Medicine of New York to Study the Effects of L-130 in the Treatment of Chronic Cluster Headache
Dr. Lauren R. Natbony to be Principal investigator Vancouver, BC – January 26, 2023 — Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) (“Lobe” or the “Company”), a North American Biopharmaceutical company... 
Via FinancialNewsMedia
Exposures Product Safety
Lobe Sciences Ltd (LOBEF) increases its portfolio with several new chemical entities (NCEs)
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Trippy Trading: Top Psychedelic Stocks For 2023
When psychedelics were first studied more than 50 years ago, researchers discovered that they were useful in assisting people in exploring a greater sense of self. After a half-century hiatus,... 
Via TheNewswire.com
Topics Cannabis
Exposures Cannabis
Lobe Sciences Announces Incorporation of Australian Subsidiary
Vancouver, British Columbia--(Newsfile Corp. - September 23, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"),... 
Via Newsfile
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.